2 Amino Acid Residues In The Peptide Chain Patents (Class 514/21.91)
-
Patent number: 11944628Abstract: The present disclosure provides compositions and methods for inducing immune tolerance in subjects suffering from metabolic diseases.Type: GrantFiled: May 11, 2018Date of Patent: April 2, 2024Assignee: Duke UniversityInventors: Priya S. Kishnani, Zoheb B. Kazi, Ankit K. Desai
-
Patent number: 11441119Abstract: Disclosed herein is a cell culture media containing L-glutamine from a set of N-acylated dipeptides Acyl-X-Q, and L-glutamine from a set of other glutamine-sources Qsource in a defined molar ratio R=n(Acyl-X-Q)/n(Qsource), wherein the variables X, Q, Acyl, R, n(Acyl-X-Q) and n(Qsource) are defined in the general disclosure. Processes of using the cell culture media are also described herein.Type: GrantFiled: March 2, 2018Date of Patent: September 13, 2022Assignee: Evonik Operations GmbHInventors: Guenter Knaup, Friedhelm Merz
-
Patent number: 11437570Abstract: A resistive switching memory device according to an exemplary embodiment includes: a first electrode; a second electrode formed to be separated from the first electrode; and an insulating layer formed near the first electrode and the second electrode, and changed to one of a high resistance state and a low resistance state when a conductive filament is controlled by a change of external humidity or a voltage applied through the first electrode or the second electrode.Type: GrantFiled: July 17, 2020Date of Patent: September 6, 2022Assignees: YONSEI UNIVERSITY, UNIVERSITY—INDUSTRY FOUNDATION (UIF), SEOUL NATIONAL UNIVERSITY R&DB FOUNDATIONInventors: Ki Tae Nam, Ouk Hyun Cho, Jang-Yeon Kwon, Min-Kyu Song, Seok Namgung, Hyeohn Kim, Yoon Ho Lee
-
Patent number: 11377418Abstract: A compound including a structure of Formula (I) and a preparation method thereof, wherein R1 is —OH, —CH2OH, or —OCOCH3; R2, R3, and R4 are independently —H, —CH3 or —F, and at least one of R2, R3, and R4 is —F. A method for treating a subject suffering from a viral disease includes administering an effective amount of said compound or a solvate thereof to the subject.Type: GrantFiled: December 3, 2020Date of Patent: July 5, 2022Assignee: Macau University of Science and TechnologyInventors: Zhi-Hong Jiang, Nanshan Zhong, Zifeng Yang, Jingrong Wang, Qitong Feng, Xiaobo Zhou, Beixian Zhou
-
Patent number: 11213509Abstract: The present invention relates, in certain embodiments, to methods for preventing and/or treating neurodegenerative damage (e.g., secondary cascade of neurodegenerative damage) and improving functional outcomes (e.g., outcomes associated with cognitive, behavior and sensorimotor function) caused by traumatic brain injury using neuroprotective lipoyl compounds. The present invention also provides, in various embodiments, compositions for use in treating and/or preventing TBI in a subject in need thereof, compounds for use in the manufacture of a medicament for treating and/or preventing TBI in a subject in need thereof, and methods of preparing a pharmaceutical composition for treating and/or preventing secondary brain damage caused by TBI.Type: GrantFiled: July 30, 2020Date of Patent: January 4, 2022Assignee: ISCHEMIX, LLCInventors: Alexander Baguisi, Reinier Beeuwkes, Ralph Casale, David A. DeWahl, Jr., Steven A. Kates, Alan S. Lader
-
Patent number: 11155528Abstract: A compound of formula (I), wherein R1 is an optionally substituted aryl or an optionally substituted heteroaryl, R2 is an optionally substituted aryl or an optionally substituted heteroaryl, and R3 is an optionally substituted alkylamino, an optionally substituted cycloalkylamino, an optionally substituted arylamino, an optionally substituted heterocyclylamino, an optionally substituted heterocyclyl, and an optionally substituted dialkylamino. A pharmaceutical composition which includes the compound of formula (I) and a pharmaceutically acceptable carrier and/or excipient. A method of treating colorectal cancer in a subject, whereby a therapeutically effective amount of the compound of formula (I) is administered to the subject.Type: GrantFiled: October 25, 2019Date of Patent: October 26, 2021Assignee: King Abdulaziz UniversityInventors: Moustafa E. El-Araby, Abdelsattar M. Omar, Martin K. Safo, Radwan S. Elhaggar, Tamer M. Abdelghany, Mostafa H. Ahmed
-
Patent number: 11053252Abstract: Fused cyclic pyrimidine compounds, including tautomers thereof, and pharmaceutically acceptable salts, prodrugs, solvates and hydrates thereof, are disclosed having the general Formula I: These compounds are useful in methods for treating cancer, selectively targeting cancerous cells via the proton coupled folate transporter, folate receptor alpha, and/or folate receptor beta pathways, inhibiting GARFTase in cancerous cells, and selectively targeting activated macrophages in a patient having an autoimmune disease, such as rheumatoid arthritis.Type: GrantFiled: February 26, 2020Date of Patent: July 6, 2021Assignees: Duquesne University of the Holy Spirit, Wayne State UniversityInventors: Aleem Gangjee, Larry H. Matherly
-
Patent number: 10744115Abstract: The present invention relates, in certain embodiments, to methods for preventing and/or treating neurodegenerative damage (e.g., secondary cascade of neurodegenerative damage) and improving functional outcomes (e.g., outcomes associated with cognitive, behavior and sensorimotor function) caused by traumatic brain injury using neuroprotective lipoyl compounds. The present invention also provides, in various embodiments, compositions for use in treating and/or preventing TBI in a subject in need thereof, compounds for use in the manufacture of a medicament for treating and/or preventing TBI in a subject in need thereof, and methods of preparing a pharmaceutical composition for treating and/or preventing secondary brain damage caused by TBI.Type: GrantFiled: April 25, 2018Date of Patent: August 18, 2020Assignee: Ischemix LLCInventors: Alexander Baguisi, Reinier Beeuwkes, Ralph Casale, David A. DeWahl, Jr., Steven A. Kates, Alan S. Lader
-
Patent number: 10292969Abstract: The present invention relates to a composition for prevention or treatment of bronchial asthma comprising a PKR inhibitor as an active ingredient. The PKR inhibitor and derivatives thereof according to the present invention can be used as a pharmaceutical for prevention, amelioration or treatment of bronchial asthma and as a supplementary health food because the PKR inhibitor and derivatives thereof reduce the total counts of inflammatory cells, eosinophils, neutrophils and lymphocytes in bronchoalveolar lavage fluid of neutrophilic severe asthma-induced mice, reduce airway inflammation and airway hyper-responsiveness, and reduce inflammatory mediators.Type: GrantFiled: December 16, 2015Date of Patent: May 21, 2019Assignee: Undustrial Cooperation Foundation Chonbuk National UniversityInventors: Yong Chul Lee, So Ri Kim
-
Patent number: 10052359Abstract: Compositions, foods, and medicaments for enhancing memory and learning function and/or cognitive function are provided. Compositions, foods, and medicaments for improving brain function and particularly enhancing memory and learning function and/or cognitive function can be provided by including a peptide including an amino acid sequence set forth in any one of SEQ ID NOs 1 to 16 as an active ingredient.Type: GrantFiled: June 16, 2015Date of Patent: August 21, 2018Assignee: KIRIN KABUSHIKI KAISHAInventors: Yasuhisa Ano, Toshiko Kutsukake
-
Patent number: 9782368Abstract: According to the invention there is provided N,N-bis-2-mercaptoethyl isophthalamide, or a pharmaceutically acceptable salt or derivative thereof, for use in regenerating ascorbate systemically and thus in the therapeutic treatment of chronic obstructive pulmonary disease.Type: GrantFiled: March 31, 2015Date of Patent: October 10, 2017Assignee: Emeramed LimitedInventors: Boyd Eugene Haley, Ragnar Axel Theodor Klingberg
-
Patent number: 9745276Abstract: The present invention relates to crystal modifications of N-{(2R)-2-[({[3,3-dibutyl-7-(methyl-thio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl]oxy}acetyl)amino]-2-phenylethanolyl}glycine (elobixibat), more specifically crystal modifications I, IV, MeOH-1, EtOH-1, 1-PrOH-1 and 2-PrOH-1. The invention also relates to a process for the preparation of these crystal modifications and to a pharmaceutical composition comprising crystal modification IV.Type: GrantFiled: April 21, 2016Date of Patent: August 29, 2017Assignee: Elobix ABInventors: Martin Bohlin, Erica Tjerneld, Andreas Vestermark, Ingvar Ymen
-
Patent number: 9707228Abstract: A dry powder formulation comprising a combination of at least a first pharmaceutically active quinolone and a second pharmaceutically active quinolone.Type: GrantFiled: May 21, 2013Date of Patent: July 18, 2017Assignees: Agency for Science, Technology and Research, National University HospitalInventors: Desmond Heng, Sie Huey Lee, Jeanette Teo, Wai Kiong Ng, Reginald Tan
-
Patent number: 9701649Abstract: The present invention relates to crystal modifications of N-{(2R)-2-[({[3,3-dibutyl-7-(methyl-thio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl]oxy}acetyl)amino]-2-phenylethanolyl}glycine (elobixibat), more specifically crystal modifications I, IV, MeOH-1, EtOH-1, 1-PrOH-1 and 2-PrOH-1. The invention also relates to a process for the preparation of these crystal modifications and to a pharmaceutical composition comprising crystal modification IV.Type: GrantFiled: April 21, 2016Date of Patent: July 11, 2017Assignee: Elobix ABInventors: Martin Bohlin, Erica Tjerneld, Andreas Vestermark, Ingvar Ymen
-
Patent number: 9566310Abstract: Disclosed herein are ?7?1 integrin modulatory agents and methods of using such to treat conditions associated with decreased ?7?1 integrin expression or activity, including muscular dystrophy. In one example, methods for treating a subject with muscular dystrophy are disclosed. The methods include administering an effective amount of an ?7?1 integrin modulatory agent to the subject with muscular dystrophy, wherein the ?7?1 integrin modulatory agent increases ?7?1 integrin expression or activity as compared to ?7?1 integrin expression or activity prior to treatment, thereby treating the subject with muscular dystrophy. Also disclosed are methods of enhancing muscle regeneration, repair, or maintenance in a subject and methods of enhancing ?7?1 integrin expression by use of the disclosed ?7?1 integrin modulatory agents. Methods of prospectively preventing or reducing muscle injury or damage in a subject are also disclosed.Type: GrantFiled: March 15, 2013Date of Patent: February 14, 2017Assignee: BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, RENOInventors: Dean Burkin, Ryan Wuebbles
-
Patent number: 9498423Abstract: The present invention discloses selenium peptide based synergistic compositions for the protection (morphology and viable numbers) of dermal papilla cells. The synergistic compositions disclosed in the present invention comprise (a) 1-O-galloyl-?-D-glucose (?-glucogallin) or 1-O-galloyl-?-D-glucose (?-glucogallin) and gallates (b) concentrate of liquid endosperm of Cocos nucifera and (c) selenopeptides.Type: GrantFiled: May 7, 2012Date of Patent: November 22, 2016Assignee: Sami Labs LimitedInventors: Muhammed Majeed, Kalyanam Nagabhushanam
-
Patent number: 9487555Abstract: This invention describes an ICE inhibitor prodrug (I) having good bioavailability. Compound I is useful for treating IL-1 mediated diseases such as rheumatoid arthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, inflammatory peritonitis, septic shock, pancreatitis, traumatic brain injury, organ transplant rejection, osteoarthritis, asthma, psoriasis, Alzheimer's disease, myocardial infarction, congestive heart failure, Huntington's disease, atherosclerosis, atopic dermatitis, leukemias and related disorders, myelodysplastic syndrome, uveitis or multiple myeloma.Type: GrantFiled: June 23, 2015Date of Patent: November 8, 2016Assignee: Vertex Pharmaceuticals IncorporatedInventors: Marion W. Wannamaker, Robert J. Davies
-
Patent number: 9327001Abstract: According to one embodiment, a nutritional supplement for suppressing an appetite while maintaining muscle mass of a subject during weight loss is provided. The nutritional supplement includes beta-hydroxy beta-methylbutyric acid (HMB), chromium, and Caralluma fimbriata.Type: GrantFiled: November 5, 2012Date of Patent: May 3, 2016Assignee: University of Florida Research Foundation, Inc.Inventors: Maria Grant, Ashay D. Bhatwadekar, Debra Carnegie
-
Patent number: 9040261Abstract: A method of preventing or inhibiting L-cystine crystallization using the compounds of formula I is disclosed. wherein A, L, R1a, R1b, and m are as described herein. The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of conditions that are causally related to L-cystine crystallization, such as comprising (but not limited to) kidney stones.Type: GrantFiled: May 24, 2013Date of Patent: May 26, 2015Assignee: NEW YORK UNIVERSITYInventors: Michael D. Ward, Jeffrey Rimer
-
Publication number: 20150141352Abstract: The present invention relates to a bone regeneration or bone formation promoting pharmaceutical composition comprising muramyl dipeptide, an analogue thereof, a derivative thereof or a pharmaceutically acceptable salt thereof. In contrast to existing passive therapeutic agents which center on bone absorption suppression based on mechanisms for reducing osteoclast functionality, the composition comprising muramyl dipeptide of the present invention promotes the differentiation of osteoblasts, which are bone forming cells, and can advantageously be used in various diseases where bone formation is required as an active therapeutic agent that does not affect osteoclast.Type: ApplicationFiled: November 1, 2012Publication date: May 21, 2015Applicant: SNU R&DB FOUNDATIONInventors: Seung Hyun Han, Ok-Jin Park, Cheol-Heul Yun
-
Publication number: 20150126462Abstract: The present invention relates to a new pharmaceutical composition containing nicotinic acid, nicotinamide, tryptophanor related compounds for positively influencing the intestinal microbiota. In certain embodiments, the pharmaceutical composition is partially or entirely released into the small intestine or large intestine.Type: ApplicationFiled: June 14, 2013Publication date: May 7, 2015Applicant: CONARIS RESEARCH INSTITUTE AGInventors: Georg Waetzig, Dirk Seegert
-
Patent number: 9023809Abstract: Disclosed are a compound of formula I, stereoisomers, pharmaceutically acceptable salts or hydrates thereof, a pharmaceutical composition comprising the same, a process for preparing the same and use thereof. The compound may also be used to prepare a medicament to treat viral infections, especially to prepare a medicament to treat hepatitis B virus and human immunodeficiency virus with little toxic side effects.Type: GrantFiled: March 27, 2008Date of Patent: May 5, 2015Assignees: The Key Laboratory of Chemistry For Natural Products of Guizhou Province and Chinese Academy of Sciences, Tianjin Institute of Pharmaceutical Research, 302 Hospital of PLA, ChinaInventors: Guangyi Liang, Bixue Xu, Changxiao Liu, Zhengming Huang, Peixue Cao, Zegui Cai, Yuming Liu
-
Patent number: 9023805Abstract: The present invention discloses and claims compositions, methods of treatment, and kits which cause an increase in the time of survival in cancer patients, wherein the cancer: (i) overexpresses thioredoxin or glutaredoxin and/or (ii) exhibits evidence of thioredoxin- or glutaredoxin-mediated resistance to one or more chemotherapeutic interventions. The present invention also discloses and claims methods and kits for the administration of said compositions to properly treat cancer patients. Additionally, the present invention discloses and claims methods and kits for quantitatively determining the level of expression of thioredoxin or glutaredoxin in the cancer cells of a cancer patient, methods of using those determined levels in the initial diagnosis and/or planning of subsequent treatment methodologies for said cancer patient, as well as ascertaining the potential growth “aggressiveness” of the particular cancer and treatment responsiveness of the particular type of cancer.Type: GrantFiled: September 16, 2010Date of Patent: May 5, 2015Assignee: BioNumerik Pharmaceuticals, Inc.Inventor: Frederick H. Hausheer
-
Patent number: 9023808Abstract: Inhibitors of HCV replication of formula (I) and the N-oxides, salts, or stereoisomers thereof, wherein the dashed line, X, R1, R2, R3, R4, R5, R6, and R7 have defined meanings; the preparation thereof; compositions containing compounds of formula (I), including bioavailable combinations with ritonavir; and the pharmaceutical uses thereof.Type: GrantFiled: January 16, 2008Date of Patent: May 5, 2015Assignees: Medivir AB, Janssen R&D IrelandInventors: Kenneth Alan Simmen, Herman Agustinus De Kock, Carl Erik Daniel Jonsson, Karl Magnus Milsson, Bengt Bertil Samuelsson, Asa Annica Kristina Rosenquist, Susana Ayesa Alverez, Bjorn Olaf Classon, Hans Kristian Wallberg
-
Publication number: 20150118224Abstract: Described herein are methods and kits for the detection of endothelial cell injury and/or activation and to the diagnostic of transplant antibody mediated rejection (ABMR). The invention further relates to methods and kits for diagnosing endothelial to mesenchymal transition (EndMT). In various embodiments, the methods comprise assessing expression of one, two or three biomarkers selected from Fascin1, Vimentin and Hsp47.Type: ApplicationFiled: April 4, 2013Publication date: April 30, 2015Inventors: Yi-Chun Xu-Dubois, Eric Rondeau, Julie Peltier, Alexandre Hertig, Isabelle Brocheriou
-
Publication number: 20150111828Abstract: The invention relates to compounds having either agonist or antagonist activities for the neurotrophins NGF and BDNF and represented by monomeric or dimeric substituted dipeptides that are analogs of the exposed portions of loop 1 or loop 4 regions of these neurotrophins near or at a beta-turn of the respective loop. N-acylated substituents of these dipeptides are biostereoisomers of the amino acid residues preceding these dipeptide sequences in the neurotrophin primary structure. The dimeric structure is produced advantageously by using hexamethylenediamine to which dipeptides are attached via their carboxyl groups. The claimed compounds displayed neuroprotective and differentiation-inducing activities in cellular models and enhanced the amount of phosphorylated tyrosine kinase A and the heat shock proteins Hsp32 and Hsp70 in the concentration range of 10?9 to 10?5 M.Type: ApplicationFiled: August 15, 2014Publication date: April 23, 2015Applicant: UCHREZHDENIE ROSSIISKOI AKADEMII MEDITSYNSKIKH NAUK NAUCHNO-ISSLEDOVATELSKY INSTITUT FARMAKOLOGIIInventors: Sergey Borisovich SEREDENIN, Alexandrovna Tatyana GUDASHEVA
-
Patent number: 9011883Abstract: Intraperitoneal administration of glutamine to reduce adhesions in the peritoneum of a patient.Type: GrantFiled: February 27, 2013Date of Patent: April 21, 2015Assignee: Ade Therapeutics Inc.Inventor: Adebola O. E. Obayan
-
Publication number: 20150099691Abstract: A dipeptide derivative as formyl peptide receptor 1 (FPR1) antagonist is provided. The dipeptide derivative is represented by formula (I), wherein: the chiral centers in formula (I) are S and R configurations respectively; each of RK and RT is selected from a group consisting of a hydrogen, a hydroxyl group, a C1-C4 alkyl-substituted hydroxyl group, a C1-C4 alkoxyl group, a carboxylic acid group, a C1-C4 alkyl nitrile-substituted, C1-C4 alkyl-substituted or C1-C4 alkoxyl-substituted amido group, a C1-C4 alkyl-substituted ester group and a benzoyl group having a C1-C4 alkyl-substituted benzene ring; and each of RM and RS is selected from a group consisting of a hydrogen, a hydroxyl group, a phenyl group, a pyridinyl group, a carboxylic acid group, a C1-C4 alkoxyl substituted ester group, and a benzoyl group having a hydroxyl-substituted, a halogen-substituted, a C1-C4 alkoxyl-substituted or a C1-C4 alkyl-substituted benzene ring.Type: ApplicationFiled: April 9, 2014Publication date: April 9, 2015Applicant: CHANG GUNG UNIVERSITYInventors: Tsong-Long Hwang, Pei-Wen Hsieh, Yin-Ting Huang, Chih-Hao Hung
-
Patent number: 8993523Abstract: The present invention provides compounds of formula M-L-M? (where M and M? are each independently a monomeric moiety of Formula (I) and L is a linker). The dimeric compounds have been found to be effective in promoting apoptosis in rapidly dividing cells.Type: GrantFiled: December 13, 2011Date of Patent: March 31, 2015Assignee: Novartis AGInventors: Zhuoliang Chen, Christopher Sean Straub
-
Publication number: 20150087578Abstract: The present invention relates to the use of compounds selected from the group consisting of Lys-(D)Pro-Thr, N-acyl Lys-(D)Pro-Thr, C-amide Lys-(D)Pro-Thr, and C-esters of Lys-(D)Pro-Thr; or a pharmaceutically acceptable salt of said compound for the treatment of inflammatory disorders. The invention also relates to the use of ?MSH for inducing tolerance.Type: ApplicationFiled: August 25, 2014Publication date: March 26, 2015Inventor: Thomas LUGER
-
Publication number: 20150087600Abstract: Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.Type: ApplicationFiled: January 21, 2013Publication date: March 26, 2015Applicant: AGIOS PHARMACEUTICALS, INCInventors: Janeta Popovici-Muller, Francesco G. Salituro, Jeffrey O. Saunders, Zhenwei Cai, Shunqi Yan, Ding Zhou
-
Patent number: 8980845Abstract: The present invention relates to a process for the enzymatic production of a dipeptide composition from a cyanophycin (CGP) or CGP-like polymer preparation by degrading the polymer preparation with an CGPase, a CGPase particularly adapted for said process, and the use of cyanophycin (CGP) or CGP-like polymers or fragments thereof, notably a dipeptide composition obtained by the process as defined above, as pharmaceutical composition, medicament, or as food or feed substitute.Type: GrantFiled: June 15, 2009Date of Patent: March 17, 2015Assignee: Westfälische Wilhelms-Universität MünsterInventors: Ahmed Sallam, Alexander Steinbüchel
-
Publication number: 20150072942Abstract: Disclosed herein is a method for reducing the rate of degradation of proteins in an animal, comprising contacting cells of the animal with certain boronic ester and acid compounds. Also disclosed herein are novel boronic ester and acid compounds, their synthesis and uses.Type: ApplicationFiled: April 8, 2014Publication date: March 12, 2015Applicant: Millennium Pharmaceuticals, Inc.Inventors: Julian Adams, Yu-Ting Ma, Ross L. Stein, Matthew Baevsky, Louis Grenier, Louis Plamondon
-
Publication number: 20150065437Abstract: The disclosure provides compositions and methods relating to aromatic-cationic peptides. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to subjects in need thereof. For example, the peptides may be administered to subjects in need of a mitochondrial-targeted antioxidant.Type: ApplicationFiled: March 20, 2014Publication date: March 5, 2015Applicant: Stealth Peptides International, Inc.Inventors: Liping Liu, Lawrence Gu
-
Publication number: 20150056300Abstract: The present disclosure generally relates to therapeutic nanoparticles. Exemplary nanoparticles disclosed herein may include about 0.1 to about 40 weight percent of a therapeutic agent and about 10 to about 90 weight percent a diblock poly(lactic) acid-poly(ethylene)glycol copolymer or a diblock poly(lactic)-co-poly(glycolic) acid-poly(ethylene)glycol copolymer, wherein the diblock poly(lactic) acid-poly(ethylene)glycol copolymer comprises poly(lactic) acid having a number average molecule weight of about 30 kDa to about 90 kDa or the diblock poly(lactic)-co-poly(glycolic) acid-poly(ethylene)glycol copolymer comprises poly(lactic)-co-poly(glycolic) acid having a number average molecule weight of about 30 kDa to about 90 kDa.Type: ApplicationFiled: October 24, 2011Publication date: February 26, 2015Applicant: BIND Therapeutics, Inc.Inventors: David Dewitt, Maria Figueiredo, Hong Wang, Greg Troiano, Young-Ho Song
-
Publication number: 20150056217Abstract: The present invention relates to the use of a TLR9 agonist and/or a TLR4 antagonist and/or a NOD2 agonist for treatment or prevention of disorders involving TLR4 activation, such as systemic sepsis and necrotizing enterocolitis.Type: ApplicationFiled: August 26, 2013Publication date: February 26, 2015Applicant: University of Pittsburgh - of the Commonwealth System of Highter EducationInventor: DAVID J. HACKAM
-
Patent number: 8962572Abstract: A bortezomib composition includes bortezomib and boric acid in a mass ratio of boric acid to bortezomib is from 1:1 to 10:1. The composition is a solid, and may be prepared by forming a liquid mixture including a solvent, bortezomib and boric acid, and lyophilizing the liquid mixture.Type: GrantFiled: October 4, 2011Date of Patent: February 24, 2015Assignee: Fresenius Kabi USA, LLCInventors: Arunya Usayapant, David Bowman
-
Publication number: 20150051161Abstract: The present invention provides compositions and methods for detecting carboxymethyl-lysine (CML) and circulating receptor for advanced glycation end (RAGE) products, and methods for correlating CML and RAGE levels with age-related disease. In particular, serum CML and/or circulating receptor for advanced glycation end (RAGE) products can be used as a clinical biomarker in diagnostics to identify people who are at a higher risk of developing adverse ageing-related outcomes.Type: ApplicationFiled: April 10, 2014Publication date: February 19, 2015Applicant: THE JOHNS HOPKINS UNIVERSITYInventors: Richard David Semba, Luigi Ferruci, Edward G. Lakatta
-
Publication number: 20150051160Abstract: The invention relates to novel tyrosine based linkers that allow the releasable connection of peptides or proteins with other molecular entities, e.g. polyethylene glycol, to processes for their preparation and their use for preparing medicaments for the treatment and/or prophylaxis of diseases.Type: ApplicationFiled: October 29, 2012Publication date: February 19, 2015Applicants: BAYER PHARMA AKTIENGESELLSCHAFT, BAYER INTELLECTUAL PROPERTY GMBHInventors: Ingo Flamme, Johannes Köbberling, Hans-Georg Lerchen, Nils Griebenow, Rudolf Schohe-Lop, Sven Wittrock, Ursula Krenz
-
Publication number: 20150045312Abstract: Methods of treating autism, autistic spectrum disorders or Fragile X syndrome comprised of administering molecules that engage the cystine-glutamate exchange (System xc?) and/or elevate the extracellular levels of glutathione in the CNS. Preferred compounds are cysteine/cystine prodrugs or N-acetyl cysteine (NAC) prodrugs.Type: ApplicationFiled: August 11, 2014Publication date: February 12, 2015Inventors: Michael Neary, Chad Beyer
-
Publication number: 20150031635Abstract: Pharmaceutical compositions and their methods of use are provided, where the pharmaceutical compositions comprise a phenolic opioid prodrug that provides enzymatically-controlled release of a phenolic opioid, and an enzyme inhibitor that interacts with the enzyme(s) that mediates the enzymatically-controlled release of the phenolic opioid from the prodrug so as to attenuate enzymatic cleavage of the prodrug.Type: ApplicationFiled: June 30, 2014Publication date: January 29, 2015Inventors: Thomas E. Jenkins, Julie D. Seroogy, Jonathan W. Wray
-
Publication number: 20150031637Abstract: The present invention relates to a combination comprising a substance with inhibiting effect on the ileal bile acid transport system (IBAT) and at least one other active substance selected from an IBAT inhibitor; an enteroendocrine peptide or enhancer thereof; a dipeptidyl peptidase-IV inhibitor; a biguanidine; an incretin mimetic; a thiazolidinone; a PPAR agonist; a HMG Co-A reductase inhibitor; a bile acid binder; and a TGR5 receptor modulator; wherein the IBAT inhibitor compound and the at least one other active substance are administered simultaneously, sequentially or separately.Type: ApplicationFiled: October 3, 2014Publication date: January 29, 2015Inventors: Per-Göran Gillberg, Hans Graffner, Ingemar Starke
-
Publication number: 20150031636Abstract: The present invention regards specific IBAT inhibitors useful in the prophylaxis and/or treatment of a liver disease. It also relates to compositions comprising these IBAT inhibitors, a method for treatment of the disorders and a kit comprising the substances or the compositions.Type: ApplicationFiled: October 3, 2014Publication date: January 29, 2015Inventors: Per-Göran Gillberg, Hans Graffner, Ingemar Starke
-
Publication number: 20150011484Abstract: The present invention provides pro-drugs of D-gamma-glutamyl-[D/L]-tryptophan, said pro-drugs are compounds of Formula I or pharmaceutically acceptable salts thereof, wherein G is C1-C8 alkyl or benzyl, T is C1-C8 alkyl or benzyl, and * is a chiral carbon in a (R) or (S) configuration, provided that when * is in the (R) configuration, at least one of G and T is C5-C8 alkyl; and use of compounds of Formula I in a pharmaceutical composition.Type: ApplicationFiled: March 30, 2012Publication date: January 8, 2015Applicant: APTOEX TECHNOLOGIES, INC.Inventors: Tim Fat Tam, Regis Leung-Toung, Yinsheng Wang, Yanqing Zhao, Tao Xin, Wanren Li, Jolanta Maria Wodzinska, Vrajlal S. Rabadia, Birenkumar Shah, Christopher John Feeney
-
Publication number: 20150011481Abstract: The present invention features interferon-free therapies for treating HCV genotype 1b, 2, 3 or 4. In one aspect, the therapies comprise administering Compound 1, ritonavir, and Compound 2 to a subject infected with HCV genotype 1b or 4, wherein the therapies do not include administration of any interferon, and the therapies last for 12 weeks. Preferably, the therapies do not include administration of any ribavirin.Type: ApplicationFiled: July 1, 2014Publication date: January 8, 2015Inventors: Regis A. Vilchez, Lino X. Rodrigues, JR., Barry M. Bernstein, Thomas J. Podsadecki, Scott C. Brun, Daniel E. Cohen, Rajeev M. Menon, Amit Khatri, Sven Mensing, Sandeep Dutta, Walid M. Awni, Emily O. Dumas, Cheri E. Klein, Tolga Baykal
-
Patent number: 8927503Abstract: The present invention provides novel compounds of the Formula (1), pharmaceutical compositions comprising such compounds and methods for using such compounds as tools for biological studies or as agents or drugs for modulating Protease Activated Receptor-2 (PAR2) and for treating a subject at risk of—or susceptible to—a disease or disorder, or having a disease or disorder associated with undesirable PAR2 activity.Type: GrantFiled: July 28, 2011Date of Patent: January 6, 2015Assignee: The University of QueenslandInventors: David Paul Fairlie, Ligong Liu, Mei Kwan Yau, Jacky Yung Suen, Robert Reid
-
Patent number: 8927499Abstract: The invention provides a method for inhibiting melanin formation composition by applying a glycine derivative, having a structure shown in the following general equation (I): wherein R1 represents a C1˜C4 alkyl group; R2 represents a hydrogen atom or a methyl group; and n represents an integer of 1˜6.Type: GrantFiled: January 21, 2014Date of Patent: January 6, 2015Assignee: Corum Inc.Inventors: Nai-Hsuan Hsu, Chiao-Yi Hsu, Ssu-Ching Wang, Ting-Wan Chen, Chu-Yi Pang
-
Patent number: 8927689Abstract: A tubular or spherical nanostructure composed of a plurality of peptides, wherein each of the plurality of peptides includes no more than 4 amino acids and whereas at least one of the 4 amino acids is an aromatic amino acid.Type: GrantFiled: November 8, 2012Date of Patent: January 6, 2015Assignee: Ramot at Tel-Aviv University Ltd.Inventors: Meital Reches, Ehud Gazit
-
Patent number: 8921319Abstract: The invention provides methods of making and using compounds of the formula shown, which are inhibitors of human plasmin and plasma kallikrein. (Formula I) The compounds are useful for the prevention of blood loss, and as components of fibrin adhesives.Type: GrantFiled: July 5, 2011Date of Patent: December 30, 2014Assignee: The Medicines Company (Leipzig) GmbHInventors: Torsten Steinmetzer, Sebastian Martin Saupe
-
Publication number: 20140364359Abstract: The invention provides di-peptide conjugated antitumor agents, pharmaceutical compositions and methods for preparation and use thereof for treating various cancer and inflammation-related diseases and conditions. The present invention addresses the shortcomings of the existing anti-tumor and anti-inflammatory drugs, particularly in that the anti-tumor agents of the invention that selectively kill cancer cells with minimal damage to normal cells.Type: ApplicationFiled: January 17, 2013Publication date: December 11, 2014Inventor: Raymond A FIRESTONE